BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real-time price. Currency in USD
46.87
-0.72 (-1.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close47.59
Open48.34
Bid0.00 x 1000
Ask0.00 x 1000
Day's range46.81 - 50.11
52-week range12.52 - 105.00
Volume1,099,504
Avg. volume1,303,204
Market cap10.629B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date12 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est43.78
  • ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
    Yahoo Finance

    ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'

    As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.

  • Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
    Zacks

    Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

    Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.

  • Better Buy: GlaxoSmithKline vs. Pfizer
    Motley Fool

    Better Buy: GlaxoSmithKline vs. Pfizer

    Both companies are weathering the bear market well as they lead the race to develop the coronavirus vaccine. But which is the better buy?

  • Coronavirus Vaccine Progress Accelerates
    Yahoo Finance

    Coronavirus Vaccine Progress Accelerates

    Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

  • Earnings Update: BioNTech SE (NASDAQ:BNTX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
    Simply Wall St.

    Earnings Update: BioNTech SE (NASDAQ:BNTX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

    A week ago, BioNTech SE (NASDAQ:BNTX) came out with a strong set of first-quarter numbers that could potentially lead...

  • Investing.com

    H.C. Wainwright Sticks to Their Hold Rating for BioNTech SE

    H.C. Wainwright analyst Robert Burns reiterated a Hold rating on BioNTech SE (NASDAQ:BNTX) on Wednesday, setting a price target of $48, which is approximately 3.96% below the present share price of $49.98.

  • BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript
    Motley Fool

    BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript

    Thank you for joining us today for BioNTech's first-quarter 2020 update call. Before we start, we encourage you to view the slides for this webcast as well as the financial results press release issued this morning, both of which are accessible on our website, in the Investors section. As shown on Slide 2, during today's presentation, we will be making several forward-looking statements.

  • Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine
    Motley Fool

    Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine

    The big pharma giant will outsource the production of medicines it sells now for a chance to halt the virus responsible for COVID-19 in its tracks.

  • Pfizer and BioNTech Begin U.S. Trials of SARS-CoV-2 Vaccine Candidate
    Motley Fool

    Pfizer and BioNTech Begin U.S. Trials of SARS-CoV-2 Vaccine Candidate

    BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) have dosed the first two U.S. volunteers with a vaccine candidate that could protect people from the coronavirus responsible for COVID-19. The partners began the global clinical trial of the vaccine in April, when they dosed a group of patients in Germany. Traditional drug development is a long process featuring clearly defined steps -- and BioNTech and Pfizer aren't exactly following them.

  • Pfizer, BioNTech set to begin U.S. coronavirus vaccine trial
    Reuters

    Pfizer, BioNTech set to begin U.S. coronavirus vaccine trial

    The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline. The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000. There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under an emergency use authorization.

  • Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
    Business Wire

    Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

  • Here's Why BioNTech Lost 18.7% in April
    Motley Fool

    Here's Why BioNTech Lost 18.7% in April

    Shares simply cooled off from an impressive run-up through March, but investors are still closely watching this biotech stock.

  • Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial
    Motley Fool

    Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial

    It was just last week that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) got permission to start a phase 1/2 clinical trial of BNT162, their SARS-CoV-2 vaccine candidate, in Germany. The safety portion of the clinical trial involves testing a range of doses from 1 microgram to 100 micrograms, and will eventually enroll 200 participants. BioNTech has developed four different variations of its mRNA vaccine.

  • German biotech firm working on COVID-19 vaccines rejects takeover approaches
    Reuters

    German biotech firm working on COVID-19 vaccines rejects takeover approaches

    German biotech company BioNTech, which has approval for human trials of potential coronavirus vaccines, has lately received several approaches about a possible takeover but has rejected them, a newspaper reported on Saturday. BioNTech chief Ugur Sahin said the company had been approached by several players in the industry, Welt am Sonntag newspaper quoted him as saying, without identifying any of the potential interested parties. A BioNTech spokeswoman confirmed the content of the interview.

  • German biotech firm working on COVID-19 vaccines not interested in takeover
    Reuters

    German biotech firm working on COVID-19 vaccines not interested in takeover

    German biotech company BioNTech <22UAy.F>, which has approval for human trials of potential coronavirus vaccines, has lately been contacted by industry players but is not interested in a takeover, a newspaper reported on Saturday. BioNTech chief Ugur Sahin said the company had been approached by several players in the industry in recent weeks, Welt am Sonntag newspaper quoted him as saying, without saying what the subject of the approaches were. A BioNTech spokeswoman confirmed the content of the interview.

  • Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany
    Zacks

    Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

    Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

  • BioNTech (BNTX) Soars: Stock Adds 5.2% in Session
    Zacks

    BioNTech (BNTX) Soars: Stock Adds 5.2% in Session

    BioNTech (BNTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Pfizer clinches coronavirus vaccine deal, sees potential in antiviral treatment
    Reuters

    Pfizer clinches coronavirus vaccine deal, sees potential in antiviral treatment

    U.S. drugmaker Pfizer Inc <PFE.N> said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus. It also finalized a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE <22UAy.F> and said the companies hope to produce millions of vaccines by the end of 2020. Data from preclinical studies of a compound that was originally developed to treat SARS - a different coronavirus that caused a major epidemic in 2003 - shows its potential to treat patients with the new coronavirus, Pfizer research chief Mikael Dolsten told Reuters in an interview.

  • Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
    Business Wire

    Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

    BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

  • Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
    Zacks

    Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?

    Is (BNTX) Outperforming Other Medical Stocks This Year?

  • Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine
    TechCrunch

    Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine

    The joint effort, confirmed Tuesday via a signed letter of intent, will see both partners work together on a messenger RNA-based vaccine that will seek to prevent people from contracting the new coronavirus. It's worth a reminder that any vaccine is going to take, at minimum, between a year and 18 months to develop and certify for general human use, so don't think that this is going to result in any kind of short-term solution. Instead, they rely on RNA to kickstart the production of proteins similar enough to the virus that they trigger the body's development of antibodies effective against the actual target.

  • Pfizer, BioNTech to co-develop potential coronavirus vaccine
    Reuters

    Pfizer, BioNTech to co-develop potential coronavirus vaccine

    The companies said they will finalise financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine over the next few weeks. Reuters reported on Sunday that the German government was trying to stop the U.S. administration from persuading CureVac, another German drugmaker working on an experimental vaccine for the coronavirus, to move its research to the United States. Pfizer and BioNTech will use research and development sites from both companies, including in the United States and Germany, the companies said.

  • Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
    Business Wire

    Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

    Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.

  • Pfizer weighs working with BioNTech on potential coronavirus vaccine - R&D head
    Reuters

    Pfizer weighs working with BioNTech on potential coronavirus vaccine - R&D head

    Pfizer Chief Scientific Officer Mikael Dolsten was one of the pharmaceutical executives who attended a meeting with U.S. President Donald Trump to discuss possible vaccines and treatments for the fast-spreading virus on Monday. Dolsten said that Pfizer, which already collaborates with BioNTech on the development of mRNA-based vaccines for influenza, is also interested in the company's efforts in coronavirus.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more